MATINS Update
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
-
Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual
- Patient recruitment for Part II in multiple cohorts progressing well
Company announcement, 01 June 2020 at 9.00 AM (EET)
Inside information
TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS trial have been presented in a poster at the virtual ASCO20 (American Society of Clinical Oncology) Annual Meeting. Separately, the Company is also pleased to announce below an update on Part II of the MATINS trial.
ASCO Poster Presentation
The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen (FP-1305), Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours.
Data were presented on all 30 patients in Part I of the trial, who had advanced solid tumours and had exhausted all standard therapeutic options. The poster included previously announced data, reporting that
-
Clevegen was well tolerated without dose-limiting toxicities;
- CLEVER-1 inhibition led to immune cell activation and downregulation of several checkpoint molecules;
- Interferon gamma and chemokine CXCL10 responses were associated with clinical responses observed in target or non-target lesions.
The poster, Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part 1 dose-escalation, safety and efficacy results, is available at the ASCO meeting library (https://meetinglibrary.asco.org) with identification code 3097.
MATINS Trial Part II update
Part II of the MATINS study has begun and the Company is pleased that patient recruitment continues to be strong, despite the COVID-19 pandemic. This Part II now contains cohorts of nine different cancers at 1.0 mg/kg dosing and three colorectal cancer (CRC) cohorts at 0.3, 1.0 and 3.0 mg/kg. Of these, the 0.3 mg/kg cohort has already recruited, with the additional two CRC cohorts expected to be recruited by mid-summer 2020. The Company intends to present data from these test cohorts (10 patients at each dosing levels) to the FDA at the end-of-phase II meeting to obtain advice ahead of expansion into the pivotal Part III stage of the trial.
Dr. Petri Bono, the Principle Investigator of the MATINS study, said: “The MATINS trial’s Part I results have shown a tolerable safety profile for Clevegen, as well as exciting clinical activity in the target lesions of several terminal cancer patients. Clevegen represents a novel mechanism of action and this macrophage checkpoint inhibition has already, in Part I of the trial, shown clinical response in immunologically ‘cold’ tumours traditionally not responsive to currently available checkpoint inhibitors. I very much look forward to continuing patient enrolment for Part II of the trial, which is progressing well for the selected tumour types.”
Dr. Markku Jalkanen, Faron's CEO, said: “Despite the study patients’ very advanced stage of disease and several lines of previous therapies, including PD-1 and CTLA-4 inhibitors, the early results from this dose finding stage of the MATINS study are very encouraging for single agent efficacy.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
Panmure Gordon (UK) Limited, Nomad and Broker
Emma Earl, Freddy Crossley (Corporate Finance)
James Stearns (Corporate Broking)
Phone: +44 207 886 2500
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: +358 (0)40 555 4727
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
About the MATINS study
The MATINS study is the first-in-human open label Phase I/II clinical trial with an adaptive design to investigate the safety and efficacy of Clevegen in selected metastatic or inoperable solid tumours. The selected tumours under investigation are cutaneous melanoma, hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancer, all known to host a significant number of Clever-1 positive tumour associated macrophages (TAM). All together these five target groups consist of approximately 2 million annual cases worldwide. Cancer patients with high Clever-1 expression are identified with a simple blood myeloid cell staining with Clevegen ("liquid biopsy").
Part I of the trial deals with tolerability, safety and dose escalation to optimize dosing. As the trial is an open label study, the Company expects to report findings as the dosing progresses. The cohort expansion during Part II will focus on identification of patients who show an increased number of Clever-1 positive circulating monocytes and the safety and efficacy of the treatment. Colorectal cancer and ovarian cancer have been selected as the first and second expansion cohorts in Part II. During Part III, the main focus will be on assessing the efficacy of Clevegen on study subjects who show an increased number of Clever-1 positive circulating monocytes, making the treatment precisely targeted and maximizing the chances of success for efficacy. The treatment, if successful, may ultimately be used as a standalone therapy or in combination with other immunotherapies like PD-1 inhibitors.
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company’s pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
Tags: